5year follow-up of a randomized clinical study comparing everolimus plus reduced-dose cyclosporine with mycophenolate mofetil plus standard-dose cyclosporine in de novo kidney transplantation: Retrospective single center assessment
详细信息 查看全文
- 作者：Takahisa Hiramitsua ; thira@nagoya2.jrc.or.jp" class="auth_mail" title="E-mail the corresponding author ; Manabu Okadaa ; Kenta Futamuraa ; Takayuki Yamamotoa ; Makoto Tsujitaa ; Norihiko Gotoa ; Shunji Narumia ; Yoshihiko Wataraia ; Asami Takedab ; Kenta Iwasakic ; Kazuharu Uchidad ; Takaaki Kobayashid ; takaaki.kobayashi@aichi-med-u.ac.jp" class="auth_mail" title="E-mail the corresponding author
- 关键词：DSA ; de novo donor ; specific antibody ; eGFR ; estimated glomerular filtration rate ; CMV ; cytomegalovirus ; STD ; standard-dose cyclosporine with mycophenolate mofetil ; EVR ; reduced ; dose cyclosporine with everolimus
- 刊名：International Immunopharmacology
- 出版年：2016
- 出版时间：October 2016
- 年：2016
- 卷：39
- 期：Complete
- 页码：192-198
- 全文大小：849 K
文摘
- class="listitem" id="list_l0005">
- class="label">•
5-year followup of randomized clinical study on everolimus (EVR)-based regimen in a single center.
- class="label">•
Efficacy and safety were compared between low-dose CSA plus EVR and standard-dose CSA plus mycophenolate mofetil.
- class="label">•
Everolimus regimen was effective for preventing CMV infection.
- class="label">•
Graft outcome including rejection, de novo DSA production, eGFR and newonset diabetes did not differ between two regimens.
- class="label">•
Hyperlipidemia and proteinuria were tolerable adverse effects when EVR trough levels were maintained between 3 and 8 ng/ml.